NASDAQ$VTYX
Ventyx Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
Ventyx Biosciences reported a net loss of $38.6 million for the first quarter of 2024. As of March 31, 2024, the company's cash, cash equivalents, and marketable securities totaled $302.6 million, expected to fund operations into at least the second half of 2026. Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 are expected to initiate in H2 2024.
- Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors
- Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026
- Topline Phase 2 data for TYK2 inhibitor VTX958 in Crohn’s disease expected early in the second half of this year.
- Initiated partnering efforts for S1P1R modulator VTX002 to support a pivotal Phase 3 trial.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$0
Forward guidance
Ventyx is focused on advancing its pipeline, including initiating Phase 2a trials for VTX3232 in Parkinson's disease and obesity, and planning for a pivotal Phase 3 trial for VTX002 in ulcerative colitis.
Tailwinds
- Initiating Phase 2a trials of VTX3232 in Parkinson’s disease and obesity in H2 2024.
- Evaluating VTX3232 in preclinical rodent models of diet-induced obesity.
- Evaluating VTX2735 in cardiovascular diseases.
- Planning for a pivotal Phase 3 trial for VTX002 in UC, supported by a partner or other source of non-dilutive financing.
- Expect to meet with EMA for a Scientific Advice meeting regarding VTX002.
Headwinds
- Potential delays in the commencement, enrollment and completion of clinical trials.
- Dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing.
- Disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials.
- Unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims.
- The use of capital resources by Ventyx sooner than expected.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q1 2024
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro